Fight Aging!

A great many proteins and other molecules might be capable of mild geroprotective effects, slightly slowing aging, or slightly improving late life health. As a general rule, proposed mechanisms for potentially geroprotective effects found in the literature are usually correct. The open question is always the size of the effect produced by those mechanisms in humans. Firm data is usually lacking, and the only practical way to determine outcomes is to run expensive, lengthy clinical studies. Those expensive, lengthy studies are not usually put together for low-cost interventions, and thus the state of uncertainty continues, fueling a supplement industry and anti-aging medical community that runs on marketing rather than facts. This paper discusses lactoferrin supplementation, a good example of a basis for therapy that falls into this category. There is lot of interesting and suggestive mechanistic evidence, but very little beyond that when it comes to outcome measures that might shed light on the impact on aging.

Lactoferrin (LF) is an iron-binding glycoprotein composed of two homologous lobes, each capable of binding one ferric iron ion. LF varies based on iron saturation, with apo-LF representing the iron-depleted form and holo-LF the iron-saturated form. LF is best understood as a multifunctional protein, with pleiotropic biological effects, including prebiotic activity, facilitation of iron absorption, and support of immune function. Clinical studies further indicate that LF promotes the growth of beneficial gut microorganisms and supports intestinal health and immunity. Because LF has been well tolerated in human trials, without a meaningful increase in adverse effects, it has the potential to benefit aging populations.

LF has traditionally been studied in the context of host defense, iron regulation, gastrointestinal health, and immune function. Evidence of LF's effect on healthy aging remains limited. LF demonstrates regulatory activity that aligns with key drivers of biological aging: preservation of epithelial barrier function, modulation of microbial composition, regulation of iron trafficking, attenuation of NF-κB-IL-6 signaling, enhancement of antioxidant defenses, and support of autophagic and mitochondrial quality control pathways. Although much of the mechanistic evidence remains preclinical, emerging human studies suggest favorable effects on inflammatory biomarkers, immune activation profiles, and iron parameters. However, whether these mechanistic and biomarker effects translate to meaningful functional outcomes in older adults remains to be established.

Link: https://doi.org/10.3390/nu18203319

Fatty liver disease, or at least the non-alcohol induced side of fatty liver disease, more properly known as metabolic dysfunction-associated steatotic liver disease (MASLD) is largely an outcome of obesity. Obesity is now known to promote an accelerated age-related accumulation of senescent cells in many tissues. It is not surprising to find cellular senescence in liver cells as an important mechanism in the progression of MASLD to more severe and ultimately fatal liver conditions. Treating the consequences of obesity with senotherapeutics does not appear a priority for the research and development community, but in fairness a great many more severe conditions have not yet made it onto that still short priority list either. There are only so many researchers and entrepreneurs in the field, and senotherapeutics can in principle treat a very large number of conditions, given the importance of cellular senescence in aging.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is sustained not only by lipid overload and hepatocellular injury but also by maladaptive responses to persistent metabolic stress. Cellular senescence has emerged as a candidate mechanism linking metabolic stress to persistent inflammation and fibrosis. This short review aims to examine how hepatocyte senescence develops and persists in MASLD, how senescent hepatocytes interact with immune surveillance, and how senescence-associated secretory phenotype (SASP) signaling contributes to fibrotic remodeling. We synthesized recent human, animal, and in vitro evidence, prioritizing mechanistic studies directly addressing hepatocyte senescence, immune cell interactions, SASP signaling, and fibrosis, while retaining landmark studies where they provided essential mechanistic context.

Current evidence indicates that senescent hepatocytes accumulate in experimental and human MASLD and can influence macrophages, hepatic stellate cells, liver sinusoidal endothelial cells, and neighboring hepatocytes. Under conditions of effective immune surveillance, senescence may remain transient and contribute to the removal of damaged cells. In a chronically injured liver, however, continued generation of senescent hepatocytes, altered immune-cell function, and persistent SASP signaling may favor their retention and promote inflammatory and fibrogenic remodeling. Important uncertainties remain, including the lack of universal senescence markers, limited direct evidence for defective senescent-hepatocyte clearance in human MASLD, and the context-dependent effects of senescence across hepatic cell types.

Overall, available evidence supports hepatocyte senescence as a plausible contributor to MASLD progression, but its pathogenic importance appears to depend on cellular context, immune competence, and the duration of the senescent state. Defining these conditions will be important for developing senescence-directed therapies without disrupting beneficial repair responses.

Link: https://doi.org/10.3389/fimmu.2026.1982821

Nuclear DNA structure determines which genes are transcribed into RNA. The molecules making up the machineries of transcription move around the nucleus to interact with every sequence of DNA they can reach. Regions of DNA that are spooled onto histone molecules and compacted are hidden, and those genes are thus silenced and not expressed. Regions of DNA that are unspooled are accessible to transcription machinery, and those genes are actively expressed. Nuclear DNA structure changes constantly, controlled by the addition and removal of decorating molecules at specific locations on DNA and histones. This is known as epigenetic regulation, a highly complex layer of interaction between cell state and pattern of gene expression.

Epigenetic control of DNA structure changes with age. Some of this may be a consequence of repeated cycles of DNA repairrand consequent depletion of molecules needed to maintain the normal status quo. The rest is a downstream consequence of other age-related changes, some of it useful, some of it maladaptive. Searching for age-related changes in epigenetic marks that are both important and harmful is not a bad strategy at this point in the state of knowledge regarding epigenetics and aging, but it is complicated by the context-dependent nature of much of epigenetics. Nonetheless, by this point in the study of epigenetics some epigenetic decorations are well studied enough to have recognizable names, which largely means the methylation of specific locations on specific histone molecules, as these affect the expression of large numbers of genes. Today's open access paper is any example of a successful foray into this part of the field, yielding a possible approach to therapies for neurodegenerative conditions.

H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain-retina axis

Epigenetic dysregulation is increasingly linked to aging and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer's disease (AD) remains unclear. We quantified the repressive epigenetic mark histone H3 lysine 9 trimethylation (H3K9me3) in post mortem retinas and brains from donors spanning normal cognition, mild cognitive impairment, and AD dementia. H3K9me3 increased early across the AD continuum in both brain and retina, correlating with cognitive impairment and neuropathological burden. H3K9me3 levels were strongly correlated between matched brains and retinas.

We characterized the in vitro inhibitory activity of ETP69, an epidithiodiketopiperazine, against suppressor of variegation 3-9 homologue 1 (SUV39H1) and other methyltransferases. In two transgenic AD mouse models (APPswe/PS1dE9 and APPswe/tauP301L/PS1tm1Mpm), we assessed ETP69 effects on cerebral H3 methylation, behavior, AD-like pathology, synaptic integrity, and proteomic profiles. This pharmacological H3K9me3 reduction consistently reduced cerebral H3K9me3 relative to other histone marks assessed, mitigated AD-like pathology, preserved synapses, and improved short-term and long-term cognitive and visual performance. Proteomics revealed that H3K9me3 derepression re-established retinal and brain proteostasis and remodeled innate immune pathways and brain-derived neurotrophic factor/nerve growth factor-inducible protein (BDNF/VGF)-granin signaling.

Hormone replacement therapy is a popular treatment for women leading up to or following menopause. Manipulating sex hormones is a very blunt strategy, with potentially significant downsides, and a high variation in outcomes between patients, but the medical community has accumulated a great deal of experience in delivering this class of therapy. In the matter of assessing how this sort of approach affects aging, the research community is presently engaged in a process of gathering as much data as possible on how aging clocks interact with various therapies thought to influence aging or age-related disease. The accuracy of the clocks in the environment of any given therapy is unknown, and the effect of the therapy on the clock is unknown, and so the way forward is to obtain as much data as possible to illuminate the space of the possible and enable better judgements on how to move ahead. The clocks and the therapies are being calibrated against one another simultaneously.

Epigenetic age acceleration (EAA) is a critical biomarker of aging. Hormone replacement therapy (HRT) is commonly used to alleviate age-related diseases, while glycemic status also influences the aging process. We aimed to investigate the association between estrogen and EAA, and the effects of HRT, EAA, and glycemic status on mortality. Mendelian randomization (MR) established causal relationships between genetically predicted estrogen receptor expression and EAA markers (HorvathAA, HannumAA, PhenoAA, and GrimAA). Using data from the National Health and Nutrition Examination Survey, we employed Cox proportional hazards models to analyze the association between HRT and mortality, exploring whether it was modified by EAA and glycemic status.

Elevated estrogen receptor α (ESR1) expression significantly decelerated PhenoAA (β -1.26). HRT significantly correlated with a reduced risk of all-cause (hazard ratio, HR: 0.65) and cardiovascular (HR: 0.52) mortality. Additionally, there was a significant three-way interaction among HRT, two types of EAA (HorvathAA and PhenoAA), and abnormal glucose status. Stratified analyses showed no significant interaction in the normal glucose subgroup; however, a significant antagonistic interaction emerged between HRT and both HorvathAA and PhenoAA in the abnormal glucose subgroup. Consequently, although HRT exhibited a protective main effect in patients with abnormal glucose, its survival benefits were significantly attenuated as their epigenetic aging accelerated.

Link: https://doi.org/10.1186/s13293-026-00959-w

It is by now well established that senescent cells promote senescence in neighboring cells. This is a useful and necessary part of the benefits of the transient presence of senescent cells in the contexts of cancer suppression and coordination of wound healing. But when senescent cell clearance falters in later life, and senescent cells begin to linger and accumulate, this promotion of further senescence makes matters worse. One of the ways in which senescent cells promote senescence is via relatively well mapped and well understood inflammatory signaling. Here, however, researchers note that there are other pathways involved, in which the signaling involves the contents of small extracellular vesicles. Interfering in senescent cell signaling as a basis for therapy is likely a more challenging path forward than selective destruction of senescent cells, but efforts are being made in both directions regardless.

Senescent cells accumulate during both physiological and pathological processes, including aging. They are characterized by the expression of the cell cycle inhibitor p16INK4A and the senescence-associated secretory phenotype (SASP). However, fibroblasts ectopically expressing p16INK4A do not exhibit a canonical SASP, leaving the mechanisms by which they communicate with their microenvironment largely unknown. Here, we show that human primary fibroblasts ectopically expressing p16INK4A release significantly more small extracellular vesicles (sEVs) than proliferating cells. Furthermore, we demonstrate that sEVs isolated from p16INK4A-expressing fibroblasts are biologically active and can mediate paracrine senescence in proliferating cells.

Specifically, treatment with these sEVs induces proliferative arrest, upregulates p16INK4A expression, and activates a DNA damage response in recipient cells. Notably, sEVs from p16INK4A-expressing cells do not induce the expression of the canonical SASP factors IL-6 and IL-8, suggesting that they promote senescence independently of a classical inflammatory response. We further demonstrate sEV-mediated transmission of paracrine senescence in two cellular models of aging: progerin expression and telomere dysfunction induced by a dominant-negative telomere mutant. In addition, sEVs isolated from fibroblasts derived from aged donors induce paracrine senescence in fibroblasts from young donors. Collectively, these findings identify sEVs released by senescent and aged cells as an important mechanism of intercellular communication and a key mediator of paracrine senescence.

Link: https://doi.org/10.18632/aging.206425

It is easier and less costly to theorize about aging than it is to run studies in mice and cells. Uncertainty also tends to inspire the generation of hypotheses, and our understanding of the fine details of degenerative aging remains in a state of considerable uncertainty. For all that biological data can now be accumulated with a level of accuracy and at rates that would shock the last generation of researchers, assembling that data into a coherent whole - in which it is fully understood and concretely proven as to how mechanisms of aging interact with one another, what is cause, what is consequence, what is more important, and what is less important - remains beyond present capabilities. There are certainly consensus views, but they are not yet set in stone. In this environment one can advance any number of reasonable novel views of how exactly aging progresses that more or less fit the data; this is a golden era for the generation of theories of aging.

Today's open access paper is an attempt to unify the traditional damage accumulation view of aging, in which forms of cell and tissue damage produce dysfunction that eventually overwhelms the organism, with the more recent hyperfunction view of aging, in which developmental programs run off the rails by continuing to operate into later life, producing dysfunction that eventually overwhelms the organism. Where these two viewpoints share common ground is around the evolutionary arguments as to why aging is near universal, in that natural selection operates more strongly on features of early life than on features of late life. Early reproductive success at the cost of later dysfunction tends to win out, so evolution near always produces biological systems that work well in early life but then fall apart. Exceptions exist, but are few and far between.

From hyperfunction to systemic amplification: reframing the logic of late-life rejuvenation

Aging is often modeled, and interventions prioritized, as the near-linear accumulation of cell-intrinsic lesions; yet the exponential acceleration of late-life mortality under the Gompertz law points to an active, program-like component shaping the trajectory. Furthermore, systemic interventions - including therapeutic plasma exchange and extracellular-vesicle-based therapies - together with the transient embryonic rejuvenation phase, can induce rapid, broadly coordinated organism-level rejuvenation on timescales difficult to attribute to gradual repair alone.

Here, we propose an integrative-first load-gain framework in which primary lesions provide the damage load, while the systemic communication architecture sets the gain: a systemic hyperfunction of intercellular signaling that converts slow cellular inputs into self-amplifying late-life acceleration. This architecture provides a mechanistic basis for both the embryonic biological-age reset and Gompertzian late-life acceleration by positioning organism-level coupling as a central gain-setting layer governing aging trajectories. It further implies regime-dependent therapeutic leverage: cell-autonomous approaches are most effective as early-life prevention and may slow progression in midlife, but durable late-life reversal requires systemic signaling reset that suppresses amplification and restores buffering capacity.

By treating rejuvenation as a shift in the organism's regulatory state rather than local lesion repair, the framework positions partial reprogramming and other cell-autonomous strategies as complementary to systemic recalibration and most effective within a rejuvenated systemic milieu.

The state of the gut microbiome is at least as influential on long term health as lifestyle choices like exercise. The composition of the gut microbiome changes with age for reasons yet to be fully explored. Inflammatory populations grow at the expense of populations producing metabolites necessary for tissue function. Connections can be drawn between near every organ and system in the body and specific metabolites or specific microbial populations influencing them. In turn the immune system and other organs influence the gut microbiome. Fortunately, it is possible to produce the lasting restoration of a more youthful gut microbiome via strategies such as flagellin immunization and fecal microbiota transplantation. Unfortunately, probiotic and related strategies are as yet incapable of producing such sizable and lasting changes, though there is hope that much more complex and carefully designed probiotic mixes could in the future approach the results obtained via fecal microbiota transplantation.

The intestine engages in communication with various distant organs through neural, immune, and endocrine pathways. This systemic interconnection mechanism is referred to as the gut-organ axis, in which gut microbiota play a central role. This review systematically examines the complex and bidirectional interactions between the gut microbiota and the brain, liver, lungs, kidneys, bones, heart, skin, germline, and immune system. Central to these interactions are microbial metabolites - fatty acids, secondary bile acids, and tryptophan derivatives - that act as crucial systemic signals engaging key receptors in the brain, liver, and beyond.

Studies demonstrated that the composition of the gut microbiota and alterations in its metabolites can directly or indirectly regulate the physiological and pathological processes of various organs. Biological therapies, such as fecal microbiota transplantation and probiotic interventions, can establish a healthy intestinal environment by reshaping the intestinal microecology, thereby positively influencing related diseases. The therapeutic landscape is rapidly evolving, with next-generation probiotics, postbiotics, and engineered strains now enabling precise, targeted remodeling of the gut ecosystem to restore host homeostasis and treat multi-organ diseases. This review articulates how the gut microbiota integrates environmental cues into a multi-organ regulatory network, underscoring its potential as a therapeutic target for systemic diseases.

Link: https://doi.org/10.1016/j.tmed.2026.100042

The only viable way to definitively establish the importance of any given mechanism of action is to create a therapy that selectively prevents or repairs that mechanism without touching the other mechanisms of aging, and then observe the outcomes in aged animals. This is a challenge, and typically the results are a surprise; until the development of senolytic therapies, no-one expected clearance of senescent cells to be so very effective at reversing age-related disease in animal models, for example. Because it is hard to determine the relative importance of mechanisms of aging, much of the aging research community often resembles a collection of small fiefdoms, each advocating for the importance of their small portion of degenerative aging, in the absence of concrete proof of that importance. This is worth bearing in mind when looking at new viewpoints, such as the concept of ferro-aging advanced here.

In recent years, with increasing research on ferroptosis, abnormal iron metabolism has gradually been recognized as an important pathological basis for aging-related diseases. Iron is an essential trace element for oxygen transport, energy metabolism, and DNA synthesis. However, excess free iron can generate large amounts of reactive oxygen species (ROS) through the Fenton reaction. This induces lipid peroxidation, DNA damage, and cellular dysfunction.

Traditionally, iron overload has been thought to promote tissue damage primarily by triggering ferroptosis; Nevertheless, recent studies have proposed a new concept distinct from ferroptosis - ferro-aging. Ferro-aging is not an acute form of cell death but rather a chronic pre-pathological state characterized by persistent lipid peroxidation and progressive cellular dysfunction. Although cells in the ferro-aging state retain membrane integrity, they can sustain irreversible damage and continuously affect the local microenvironment through the formation of the senescence-associated secretory phenotype (SASP), ultimately contributing to tissue functional decline and systemic aging,

This review systematically summarizes the molecular basis of ferro-aging, with a focus on the central role of ACSL4 in promoting membrane lipid remodeling and sustaining chronic lipid peroxidation. We discuss how ACSL4-associated ferro-aging contributes to the pathogenesis of osteoporosis (OP), osteoarthritis (OA), and intervertebral disc degeneration (IVDD) by disrupting local microenvironmental homeostasis, driving metabolic reprogramming, amplifying inflammatory SASP signaling, and impairing the function of key cell types such as osteoblasts, chondrocytes, and nucleus pulposus cells.

Link: https://doi.org/10.1186/s12964-026-03194-3

Cells contain hundreds of mitochondria, constantly fusing together, replicating by splitting apart, and swapping component parts. Mitochondrial function is vital to cell health, and declining mitochondrial function is an important component of degenerative aging. Some of the answers as to why mitochondrial function declines with age are likely buried somewhere in the complex interactions of mitochondrial structure, the dynamics of mitochondrial fusion and fission, and the operation of the mitochondrial quality control processes of mitophagy. Mitophagy is both necessary to maintain function by destroying worn mitochondria, but it also seems quite sensitive to changes in structure and size of mitochondria, as happens when the dynamics of fusion and fission change.

In today's open access paper, researchers demonstrate that compounds that improve the activity of mitofusin, a protein that is important in mitochondrial fusion, lead to improved mitochondrial function and slowed aging in short-lived nematode worms. This is perhaps more interesting than the average result of this nature because at least one mitofusin activator is somewhere in the process of development as a human therapy. Nonetheless, when it comes to modulating mitochondrial dynamics, a survey of the literature will show papers in which benefits arise from inducing greater fission, greater fusion, and greater equilibrium. In short, it is complicated, and one shouldn't take any individual result as promising without looking at contradictions that characterize the broader field of such efforts.

Mitofusin Activation Delays Aging in Caenorhabditis elegans

Age-linked tissue dysfunction is associated with mitochondrial degeneration manifested as organelle fragmentation and respiratory dysfunction. Efforts to mitigate downstream consequences of mitochondrial degeneration, as with reactive oxygen species (ROS) scavengers, have not translated to the human condition. We posit that intrinsic fusion-mediated mechanisms for mitochondrial protection modulate aspects of aging linked to mitochondrial abnormalities. In C. elegans roundworms mitochondrial fusion is mediated by the mitofusin ortholog Fuzzy Onion-1 (fzo-1).

Here, the addition of a mitofusin inhibitor, MFI8, to cultures of age-synchronized C. elegans shortened worm lifespan in a concentration-dependent manner. Reciprocally, the mitofusin activators Chimera and 8015-P2 prolonged worm survival in a dose-dependent manner. The pro-survival effect of Chimera was absent in worms lacking its protein target, FZO-1, and at lower concentrations Chimera-amplified survival was further increased by absence of the mitochondrial fission protein that acts in opposition to fzo-1, DRP-1. The mitofusin activator 8015-P2, which is more potent than Chimera, exhibited greater anti-aging effects on lifespan and improved worm healthspan measured as forced swimming activity and resistance to thermal and oxidative stresses.

These proof-of-concept worm studies identify aging phenotypes reciprocally related to fzo-1/mitofusin activation status. As 8015-P2 is under development for use in human neurodegenerative diseases, it might alleviate aging phenotypes evoked by mitochondrial degeneration in higher species.

At the high level, exposing a cell to the Yamanaka factors first does nothing, then later rejuvenates epigenetic control over nuclear DNA structure and gene expression, and then later still causes the cell to dedifferentiate into an induced pluripotent stem cell. Much of the challenge in building rejuvenation therapies based on reprogramming via Yamanaka factors lies in ensuring sufficient epigenetic rejuvenation (desired and beneficial) without any dedifferentiation (undesirable and potentially cancerous) in a tissue environment in which different cell types may require different doses and timing of exposure to Yamanaka factors. With that in mind, the research here is an interesting attempt to close the door on dedifferentiation as a possibility. It remains to be seen as to how useful this will be, but any robust way to ensure that reprogramming will remain partial at all doses and durations will be a very valuable technology.

Mesenchymal stem cells (MSCs) are widely used in cell therapies; however, replicative senescence during in vitro expansion limits their potency and consistency. Partial reprogramming has emerged as a promising strategy to rejuvenate aged cells, yet concerns regarding unintended pluripotent conversion have hindered its translational application.

Here we developed a circular RNA (circRNA)-based platform enabling safe partial reprogramming and rejuvenation of MSCs. We generated a lipid nanoparticle (LNP)-delivered circRNA co-expressing OCT4, SOX2, and KLF4 (circ-OSK) to achieve transient and coordinated expression of partial reprogramming factors without genomic modification in MSCs. Using a rigorously validated droplet digital PCR (ddPCR) system targeting the pluripotency marker ESRG, we demonstrated that circ-OSK delivery alone is insufficient to transform MSCs into induced pluripotent stem cells (iPSCs).

Circ-OSK-mediated partial reprogramming significantly rejuvenated senescent late-passage MSCs by reducing senescence-associated β-galactosidase activity, DNA damage markers, and inflammatory cytokine secretion, while preserving canonical MSC surface markers and genome stability, and restoring proliferative, migratory, and tri-lineage differentiation capacities at a level comparable to early-passage MSCs. The rejuvenated MSCs generated through this process are defined as partially reprogrammed MSCs (prMSCs). Further RNA-seq analysis revealed that prMSCs restored youthful gene expression and promoted a stress resilient and regenerative transcriptional program via repressing the PI3K-Akt signaling pathway. Combined RNA-seq and SNP array analysis confirmed circ-OSK-mediated partial reprogramming retained MSC identity and genome integrity without pluripotent conversion.

Link: https://doi.org/10.1186/s13287-026-05193-0

Researchers here report on the results of screening a few thousand proteins found in blood plasma for those where levels correlate with (a) risk of mortality and (b) organ-specific biological age, using a consensus approach to determining those biological age measures from proteomic data. The usual caveats apply regarding whether or not such an aging clock is actually measuring biological age, or would still produce decent data if an anti-aging intervention were involved, but gathering more data on the performance of such clocks is nonetheless a potentially useful activity.

We aimed to identify plasma proteins associated with all-cause mortality and determine their relationships with chronic disease burden and biological aging at both the organismal and organ-specific levels, thereby providing insights into the biological mechanisms underlying healthy aging and longevity. We conducted a prospective cohort study of 1,025 older adults from the LonGenity study, analyzing 4,265 plasma proteins. Associations between protein levels and all-cause mortality were evaluated using Cox proportional hazards regression over a mean follow-up of 8.05 years. Mortality-associated proteins were further examined for their relationships with chronic disease burden and proteome-derived measures of organismal and organ-specific biological aging. Findings were independently validated in 1,124 participants from the Baltimore Longitudinal Study of Aging (BLSA).

Seventeen plasma proteins were significantly associated with all-cause mortality. Higher levels of epidermal growth factor receptor (ERBB1) and anthrax toxin receptor 2 (ANTXR2) were associated with lower mortality risk and younger biological age across multiple organ systems. Conversely, higher levels of growth differentiation factor 15 (GDF15), human epididymis protein 4 (HE4), and insulin-like growth factor-binding protein 2 (IGFBP-2) were associated with increased mortality and older biological age across multiple organ systems. Specifically, elevated MIC-1 was associated with older organismal biological age, whereas ERBB1 was associated with younger liver biological age. These associations were independently replicated in the BLSA cohort.

Link: https://doi.org/10.70401/Geromedicine.2026.0042

Cells become senescent constantly throughout life, usually upon reaching the Hayflick limit to replication, but also in response to injury, high levels of cell stress, or potentially cancerous damage. Senescent cells cease to replicate, grow in size, and secrete pro-inflammatory signals to attract the attention of the immune system. In youth, the immune system clears senescent cells rapidly, but this becomes less efficient with advancing age for a range of reasons yet to be fully explored. Senescent cells appear to alter their biochemistry in ways that inhibit immune clearance, but the immune system as a whole also becomes less effective at all of its tasks. Senescent cells linger, accumulate, and disrupt tissue structure and function with their inflammatory signaling.

The vascular system is vital to health, and many of its issues are known to start with dysfunction in the inner lining of vessels, the vascular endothelium. Inflamed regions of endothelial tissue, populated by growing numbers of senescent endothelial cells, are an early feature in the development of the fatty, obstructive plaques of atherosclerosis, disruption of the blood-brain barrier allowing leakage into the brain, dysfunctional smooth muscle that degrades the ability of vessels to contract and dilate appropriately, and forth.

In today's open access paper, researchers outline a possible target for reduction of the burden of cellular senescence in aged blood vessels. MTR4 expression appears to reduce the pace at which vascular endothelial cells become senescent, but unfortunately declines with age. Enhancing expression is shown to extend life in short-lived nematode worms, suggesting that trying a lifespan study in mice is worth the effort. The vascular endothelium is a challenging target for gene therapies, however, because there is so very much of it. Even though the endothelium is just about the first destination for any suitably engineered vector that is injected intravenously, it would be challenging to deliver enough vector to cover the entire endothelium without an excessive amount spilling over to end up in liver tissue and cause issues there.

MTR4: A Conserved Youth Factor for Vascular Endothelium

Vascular endothelial cells (VECs) form the inner lining of blood vessels and act as a critical interface between the circulation and surrounding tissues. Beyond their role as a physical barrier, VECs dynamically regulate vascular tone, permeability, inflammation, and hemostasis, thereby maintaining multi-organ homeostasis and modulating disease pathogenesis. Chronically exposed to hemodynamic and metabolic stress, VECs are among the first cell types to acquire age-related damage. Senescent VECs undergo irreversible cell cycle arrest and acquire a pro-inflammatory senescence-associated secretory phenotype (SASP), which propagates local and systemic chronic inflammation. Endothelial dysfunction is now recognized as a central driver of major age-related disorders.

Here, we identify MTR4, an evolutionarily conserved RNA helicase and nuclear RNA exosome cofactor, as a novel regulator of VEC senescence. MTR4 protein declines markedly in senescent human umbilical vein endothelial cells (HUVECs) and aged mouse aortas, independent of general cell cycle exit. Mechanistically, senescence-induced upregulation of the E3 ubiquitin ligase synoviolin 1 (SYVN1) promotes K638-linked ubiquitination and proteasomal degradation of MTR4. MTR4 depletion drives proliferating HUVECs into premature senescence, whereas its overexpression restores a youthful phenotype in senescent cells by binding BUB3 to stabilize BUB3 and sustain BUBR1 expression.

In mice, endothelial Mtr4 knockdown promotes vascular dysfunction and multi-organ aging, while endothelium-specific Mtr4 overexpression alleviates these phenotypes. In C. elegans, mtr-4 overexpression dramatically extends lifespan, comparable to classic longevity models and surpassing most single-gene interventions, while its knockdown accelerates aging. Our findings establish MTR4 as a critical guardian of endothelial homeostasis and organismal aging, with strong translational potential for mitigating age-related vascular dysfunction.

Education, intelligence, socioeconomic status, and healthy longevity are all correlated with one another in human populations. No concrete determination of the mechanisms that make this the case has yet been established, but there is no shortage of hypothesizing on the topic. Does education produce an effect through the greater socioeconomic status that it tends to produce, or is there, for example, some physical benefit arising from a greater use of the brain during developmental years that lasts for long enough to affect neurodegeneration in late life? Or it is that more intelligent people tend to be more educated, and thus intelligence is the factor that one needs to look at for causation? And so forth. Here, researches present results that argue more for a contribution of physical effects in the brain than for other possibilities.

Lower educational attainment has been identified as a major risk factor for Alzheimer's disease and related dementias (ADRD). However, little is known about whether and how much of this association reflects a causal effect from education to ADRD. Part of the challenge in distinguishing correlation from causation is that third factors, such as childhood circumstances, socioeconomic background, and genetics, may confound the relationship between education and ADRD. Also, there may be individual characteristics, such as self-control, that drive both behavioral risk factors and educational attainment.

We overcome these challenges by combining a natural experiment with dementia data constructed from administrative health records for a large cohort. In 1972, England, Scotland, and Wales increased the minimum age at which students could drop out of school from 15 to 16 years of age. The reform affected only students born after September 1, 1957, generating a discontinuity in the relationship between education and date of birth. We exploit this discontinuity to estimate the causal effect of education on dementia incidence.

We found that this additional schooling induced by a natural experiment in the United Kingdom in the early 1970s subsequently reduced the cumulative incidence of ADRD in affected cohorts by approximately 0.88%. These results suggest that ADRD incidence can be modified by social policy, a welcome finding given the expected exponential growth in cases of dementia and their large costs. Encouragingly, we also found that the school reform mitigated the genetic risk of developing ADRD - rejecting the common perception that the influence of genetics on diseases such as ADRD cannot be altered by environmental interventions.

Link: https://doi.org/10.1073/pnas.2529506123

Despite a number of approved devices and some widely used protocols (that are not very consistent from device to device and provider to provider), few electromagnetic therapies have demonstrated consistent benefits. Some research groups are focused on applying electromagnetic fields to the brain, specifically ultrashort wave fields that may act to reduce inflammation. Here, researchers note that short wave electromagnetic therapy improves the drainage of cerebrospinal fluid from the brain into the glymphatic system. This drainage declines with age for a range of different reasons, and this contributes to neurodegeneration by encouraging protein aggregates and other metabolic waste to accumulate in brain tissue. One of the reasons why drainage declines is that the water channel AQP-4 becomes mislocalized in astrocyte cells. AQP-4 needs to be in the extended endfeet structures of astrocytes, which wrap around the perivascular spaces used to transport fluid away from the brain, and in aged tissues AQP-4 is not correctly localized in large enough amounts for efficient passage of fluid. The electromagnetic therapy appears to function by improving AQP-4 localization.

The glymphatic system clears cerebral waste, yet strategies to enhance its function remain elusive. Here, we show that 40.68 MHz ultrashort wave (USW) rapidly enhances glymphatic bulk flow in healthy mice within 10 minutes. USW potentiates both glymphatic influx and efflux, concomitant with increased Delta wave neuronal synchronization, as confirmed by local field potentials and electroencephalograms. Chemogenetic silencing confirms that USW-driven glymphatic enhancement depends on neuronal activity, while pharmacological blockade of aquaporin-4 (AQP4) abolishes the effects, revealing dual reliance on neural dynamics and astrocytic water channels.

Mechanistically, USW-induced Delta oscillations promote AQP4 polarization, coupling synchronized firing to perivascular AQP4 redistribution. Moreover, USW ameliorates traumatic brain injury-induced cerebral edema and improves cognitive deficits in Alzheimer's model mice by restoring glymphatic function. Our findings establish USW as a non-invasive neuromodulatory strategy for enhancing glymphatic clearance, offering therapeutic potential for neurological disorders characterized by glymphatic dysfunction.

Link: https://doi.org/10.1126/sciadv.aeh8870

Lysosomes are structures within cells packed full of enzymes capable of breaking down proteins and structures into raw materials; they serve as recycling centers. Lysosomes are the final destination of damaged or unwanted proteins and structures flagged for destruction by the cellular maintenance processes of autophagy. Lysosomes are known to become dysfunctional with age, for reasons that are not fully explored. Some of it is a matter of changes in the expression of relevant genes, some of it is a matter of the accumulation of persistent metabolic waste that lysosomes cannot effectively break down. Given enough of that waste, lysosomes become bloated and inefficient. If a cell cannot effectively recycle, it becomes dysfunctional, inflammatory, and eventually dies. The more that this happens, the more that it contributes to degenerative aging.

Lysosomal dysfunction didn't make it into the Hallmarks of Aging as a headline category of its own. Arguably it should have. The earlier Strategies for Engineered Negligible Senescence (SENS) proposals included lysosomal dysfunction as a part of the problem of the aggregation of persistent metabolic waste inside cells, and did not focus all that much on harmful epigenetic change, save as it exists as a maladaptive reaction to other forms of molecular damage.

In today's open access paper, researchers report on novel findings in lysosomal aging, and show that it is possible to build a sufficiently complex signature of lysosomal aging from these findings to enable the creation of an aging clock. That one can build a decent aging clock from this data doesn't definitively indicate that this is an important cause of degenerative aging, however. That has to be separately determined the old-fashioned way. As is usually the case, the fastest path to demonstrating relevance as a contributing cause of aging is to find a way to reverse the specific observed changes in isolation, and then observe the outcome. Unfortunately one has to establish a path to therapy, then see whether or not it is viable, and not the other way around.

The Lysosomal Clock: Are We Only as Old as Our Lysosomes?

Lysosomes are a major organelle involved in intracellular degradation, membrane traffic, and metabolic signaling, but how their biochemical composition changes during normal aging remains poorly defined. Researchers now combine lysosome purification with metabolomics and lipidomics across tissues, species and ages to reveal a conserved signature of lysosomal aging characterized by accumulation of glycerophosphodiesters (GPDs) and cystine, and remodeling of bis(monoacylglycero)phosphate (BMP). Strikingly, these changes are largely obscured in whole-tissue analyses and resemble metabolic abnormalities associated with lysosomal storage disorders, including CLN3 disease and cystinosis.

The signature develops progressively with age, can predict chronological age, and is attenuated by caloric restriction in peripheral tissues but not in the brain. Within the brain, age-dependent metabolite accumulation is particularly prominent in microglia and is also detected in neurons, linking lysosomal aging to cell populations central to neurodegenerative disease. These findings define an organelle-level metabolic clock, suggesting that one might be only as young as one's lysosomes. Establishing whether GPDs, cystine, and BMP remodeling merely mark lysosomal age or actively contribute to declining lysosomal degradation and membrane traffic may uncover a metabolic connection between physiological aging, lysosomal storage disorders, and vulnerability to late-onset neurodegeneration.